Document 0123
 DOCN  M9620123
 TI    Immunization trial of cats with a replication-defective adenovirus type
       5 expressing the ENV gene of feline immunodeficiency virus.
 DT    9602
 AU    Gonin P; Fournier A; Oualikene W; Moraillon A; Eloit M; Laboratoire de
       Genetique Moleculaire, Genetique virale, INRA,; Ecole Nationale
       Veterinaire, Maisons Alfort, France.
 SO    Vet Microbiol. 1995 Aug;45(4):393-401. Unique Identifier : AIDSLINE
       MED/96021593
 AB    Our aim was to develop a recombinant replication-defective adenovirus
       suitable for the vaccination of cats against feline immunodeficiency
       virus. We first demonstrated that this vector was able to transfer a
       marker gene (E. coli beta-galactosidase) in feline cells in vitro. We
       then constructed an adenovirus type 5 expressing the Feline
       Immunodeficiency Virus (FIV) envelope (ENV) gene of the Wo isolate in
       the absence of the rev gene (Ad-ENV-Wo). Ad-ENV-Wo was then tested in
       four cats in a 3 injections scheme (at day 0, day 30 and day 210). Four
       other control cats received Ad-gp50, a similar recombinant adenovirus
       expressing gp50 (Ad-gp50) of pseudorabies virus (PRV). Viruses were
       formulated in two different kind of oil adjuvants (water/oil and
       water/oil/water), a protocol previously shown to enhance the immune
       response against the virus-induced protein. The control cats developed
       neutralizing antibodies against PRV, demonstrating the potency of
       recombinant human adenovirus 5 (Ad5) as a vector in cats. Antibody
       responses appeared after the first injection and were higher with the
       water/oil/water formulation than with the water/oil controls. However,
       none of the four cats vaccinated with Ad-ENV-Wo developed antibodies
       against two peptides of the envelope protein. Animals were challenged
       with 20 infectious doses 50% of the strain Wo. All of them developed
       antibodies against FIV within 4 to 5 weeks, and FIV virus could be
       isolated from all.
 DE    beta-Galactosidase/BIOSYNTHESIS/GENETICS
       Adenoviridae/*IMMUNOLOGY/PHYSIOLOGY  Animal  Antibodies, Viral/BLOOD
       Antibody Formation  Cats  Cell Line  Comparative Study  Defective
       Viruses/*IMMUNOLOGY/PHYSIOLOGY  Escherichia coli/GENETICS  Feline
       Acquired Immunodeficiency Syndrome/BLOOD/IMMUNOLOGY/  *PREVENTION &
       CONTROL  Gene Products, env/BIOSYNTHESIS/GENETICS  *Genes, env  Human
       Immunization  Immunodeficiency Virus, Feline/GENETICS/*IMMUNOLOGY
       Recombinant Proteins/BIOSYNTHESIS  Support, Non-U.S. Gov't  Transfection
       *Viral Vaccines  Virus Replication  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).